A Phase 2 interventional study of Comparator Dose (40mg) MDMA HCl and Active Dose 2 (100 mg) MDMA HCl in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 17th largest by enrollment, is one of 2 that started in 2013, is one of 28 in phase 2, and was the 7th registered.
2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 21–70
Sunstone Medical · Sites in United States
Ages 18+
Sheba Medical Center · Sites in Israel
Ages 18–75
Johns Hopkins University · Sites in United States
Ages 21+
Bronx VA Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 30 · Phase 3 6
First in 2004; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 69 across 2,202 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 25 across the 38 interventional studies. Of the 22 that completed or were terminated, 16 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lykos Therapeutics, one of the names counted as Resilient Pharmaceuticals. Under that name alone:
Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals: none open now, none under way, none of them phase 3. Of 17 finished, 15 (88%) have results posted.
Among the 20 studies in Stress Disorders, Post-Traumatic by Resilient Pharmaceuticals, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2013, is one of 13 in phase 2, and was the 7th registered.
Resilient Pharmaceuticals’s Stress Disorders, Post-Traumatic studies by the year they started, since 2004.
4 of the studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT07569159Sunstone MedicalMDMA Therapy in Veterans With PTSD | 2027-04-01 |
| NCT05837845Patricia SuppesMDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder | 2027-05 |
| NCT05732155Guy SchusheimPreliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Resilient Pharmaceuticals’s 20 in Stress Disorders, Post-Traumatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if MDMA in combination with therapy is safe and effective in people with chronic, treatment-resistant PTSD.
The main questions it aims to answer are:
Researchers will compare two active doses (100 mg and 125 mg) of MDMA-assisted therapy versus a comparator dose of 40 mg MDMA-assisted therapy to determine if there is a reduction in PTSD symptoms.
Participants will undergo three non-drug preparatory sessions, three MDMA-assisted therapy sessions and three non-drug integrative therapy sessions after each MDMA-assisted therapy session.
This Phase 2 pilot study is a randomized, double-blind, dose response study to examine the safety and efficacy of MDMA-assisted psychotherapy in 23 subjects with chronic, treatment-resistant PTSD of at least six months duration. This study assessed two active doses of MDMA, active dose 1 (100 mg) and active dose 2 (125 mg), to a comparator dose of MDMA (40 mg) during psychotherapy sessions. The initial dose of MDMA was followed 1.5 to 2.5 hours later by an optional supplemental dose of MDMA that was half the size of the first dose. MDMA was administered orally in two experimental sessions lasting up to eight hours and scheduled three to five weeks apart.
Subjects were prepared for MDMA-assisted psychotherapy in three preparatory sessions prior to the first experimental session, and worked with the same pair of therapists throughout the study. After each experimental session, three integrative sessions were scheduled with the subject, including one integrative session the morning after the experimental session. During integrative sessions, subjects processed and connected their thoughts and feelings about the experience with their therapist team.
Subjects who received the comparator dose (40 mg) were given the option to enroll in Stage 2, where they underwent three open-label MDMA-assisted psychotherapy sessions. 100 mg of MDMA was administered in the first session and therapists determined whether to increase to 125 mg of MDMA for the second and third experimental sessions. People who received 125 mg of MDMA during the first two experimental sessions received the same dose during an open-label third experimental session. People who received 100 mg of MDMA during the first two sessions were able to choose, in consultation with their therapist, to either continue to receive 100 mg in a third session or to increase their dose to 125 mg.
A blinded independent rater (IR) assessed the severity of PTSD symptoms at baseline, one month after the second experimental session (the primary endpoint), two months after the third open-label experimental session, and at equivalent points in Stage 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive an initial dose of comparator dose midomafetamine HCl (40 mg) during each of two therapy sessions.
Drug: Comparator Dose (40mg) MDMA HCl · Behavioral: Psychotherapy
Participants receive an initial dose of Active Dose 2 midomafetamine HCl (100 mg) during each of two therapy sessions.
Drug: Active Dose 2 (100 mg) MDMA HCl · Behavioral: Psychotherapy
Participants receive an initial dose of Active Dose 1 midomafetamine HCl (125 mg) during each of two therapy sessions.
Drug: Active Dose 1 (125 mg) MDMA HCl · Behavioral: Psychotherapy
An initial comparator-dose of 40 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (20 mg).
Also known as: 3,4-methylenedioxymethamphetamine, midomafetamine HCl, midomafetamine, MDMA
An initial dose of full-dose 100 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (50 mg).
Also known as: 3,4-methylenedioxymethamphetamine, midomafetamine HCl, midomafetamine, MDMA
An initial dose of full-dose 125 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (62.5 mg).
Also known as: 3,4-methylenedioxymethamphetamine, midomafetamine HCl, midomafetamine, MDMA
Non-directive manualized therapy
Also known as: Manualized MDMA-assisted psychotherapy
Change in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score From Baseline to One Month Post 2nd Experimental Session
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Change in PTSD Diagnostic Scale (PDS) From Baseline to One Month Post 2nd Experimental Session
The PTSD Diagnostic Scale (PSD) is self-report measure designed to follow DSM-IV criteria for assessing PTSD. It contains 49 items, with responses made on a four-point scale, ranging from 0 ("not at all") to 3 ("five or more times a week"). The PDS consists of a list of 12 potential traumatic events, 12 items addressing elements of the traumatic event, 17 symptom items, and 9 items assessing impact on areas of life function. Items addressing elements of the traumatic event and life function are answered as either present or not present (Yes or No). The 17 items are summed to create a symptom severity score, with higher scores indicating a greater number and/or intensity of PTSD symptoms. The symptom severity score ranges from 0 to 51.
Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Change in Beck Depression Inventory II (BDI-II) From Baseline to One Month Post 2nd Experimental Session
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.
Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Change in Global Assessment of Functioning (GAF) Total Score From Baseline to One Month Post 2nd Experimental Session
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.
Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to One Month Post 2nd Experimental Session
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.
Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Change in Dissociative Experiences Scale (DES-II) From Baseline to One Month Post 2nd Experimental Session
The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. The scale consists of statements describing facets of dissociation. Respondents indicate how often the specific experience happens to them, from "never" to "always." The DES-II uses the same items but with responses made on a 10 point scale from "0%" to "100%" of the time. The scale is scored by treating percentages as single digits to produce a total score with higher scores indicating greater severity. The total score ranges from 0 to 100.
Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Change in Posttraumatic Growth Inventory (PTGI) From Baseline to One Month Post 2nd Experimental Session
The PTGI is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales: relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. PTGI scores on a 6 point scale are: 0 - I did not experience this as a result of my crisis; 1 - I experienced this change to a very small degree as a result of my crisis; 2 - I experienced this change to a small degree as a result of my crisis; 3 - I experienced this change to a moderate degree as a result of my crisis; 4 - I experienced this change to a great degree as a result of my crisis; and 5 - I experienced this change to a very great degree as a result of my crisis. A total score is calculated by summing the responses to all 21 items, each rated on a 6-point scale, with higher scores indicating greater post-traumatic growth
Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Candidates were recruited via Internet advertisements and referrals from mental health professionals.
| Milestone | Comparator Dose MDMA (40 mg) and Psychotherapy | Active Dose 2 MDMA (100 mg) and Psychotherapy | Active Dose 1 MDMA (125 mg) and Psychotherapy |
|---|---|---|---|
| Started | 6 | 9 | 13 |
| Completed | 6 | 9 | 12 |
| Not completed | 0 | 0 | 1 |
| Milestone | Comparator Dose MDMA (40 mg) and Psychotherapy | Active Dose 2 MDMA (100 mg) and Psychotherapy | Active Dose 1 MDMA (125 mg) and Psychotherapy |
|---|---|---|---|
| Started | 5 | 0 | 0 |
| Completed | 5 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.
| score on a scale | Active Dose 1 (125 mg) MDMA and Psychotherapy | Active Dose 2 (100 mg) MDMA and Psychotherapy | Comparator-dose (40 mg) MDMA and Psychotherapy |
|---|---|---|---|
| Change in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score From Baseline to One Month Post 2nd Experimental Session | -26.3 ± 29.52 | -24.4 ± 24.22 | -11.5 ± 21.21 |
The PTSD Diagnostic Scale (PSD) is self-report measure designed to follow DSM-IV criteria for assessing PTSD. It contains 49 items, with responses made on a four-point scale, ranging from 0 ("not at all") to 3 ("five or more times a week"). The PDS consists of a list of 12 potential traumatic events, 12 items addressing elements of the traumatic event, 17 symptom items, and 9 items assessing impact on areas of life function. Items addressing elements of the traumatic event and life function are answered as either present or not present (Yes or No). The 17 items are summed to create a symptom severity score, with higher scores indicating a greater number and/or intensity of PTSD symptoms. The symptom severity score ranges from 0 to 51.
| score on a scale | Active Dose 1 (125 mg) MDMA and Psychotherapy | Active Dose 2 (100 mg) MDMA and Psychotherapy | Comparator-dose (40 mg) MDMA and Psychotherapy |
|---|---|---|---|
| Change in PTSD Diagnostic Scale (PDS) From Baseline to One Month Post 2nd Experimental Session | -11.3 ± 11.26 | -10.0 ± 10.44 | -4.2 ± 3.13 |
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.
| score on a scale | Active Dose 1 (125 mg) MDMA and Psychotherapy | Active Dose 2 (100 mg) MDMA and Psychotherapy | Comparator-dose (40 mg) MDMA and Psychotherapy |
|---|---|---|---|
| Change in Beck Depression Inventory II (BDI-II) From Baseline to One Month Post 2nd Experimental Session | -11.0 ± 13.68 | -9.9 ± 13.26 | -11.5 ± 7.79 |
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.
| score on a scale | Active Dose 1 (125 mg) MDMA-assisted Therapy | Active Dose 2 (100 mg) MDMA-assisted Therapy | Comparator Dose (40 mg) MDMA-assisted Therapy |
|---|---|---|---|
| Change in Global Assessment of Functioning (GAF) Total Score From Baseline to One Month Post 2nd Experimental Session | 0.6 ± 10.57 | 2.4 ± 9.63 | 1.5 ± 4.59 |
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.
| score on a scale | Active Dose 1 (125 mg) MDMA and Psychotherapy | Active Dose 2 (100 mg) MDMA and Psychotherapy | Comparator-dose (40 mg) MDMA and Psychotherapy |
|---|---|---|---|
| Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to One Month Post 2nd Experimental Session | -2.0 ± 4.69 | -3.6 ± 6.19 | -0.8 ± 2.48 |
The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. The scale consists of statements describing facets of dissociation. Respondents indicate how often the specific experience happens to them, from "never" to "always." The DES-II uses the same items but with responses made on a 10 point scale from "0%" to "100%" of the time. The scale is scored by treating percentages as single digits to produce a total score with higher scores indicating greater severity. The total score ranges from 0 to 100.
| score on a scale | Active Dose 1 (125 mg) MDMA-assisted Therapy | Active Dose 2 (100 mg) MDMA-assisted Therapy | Comparator Dose (40 mg) MDMA-assisted Therapy |
|---|---|---|---|
| Change in Dissociative Experiences Scale (DES-II) From Baseline to One Month Post 2nd Experimental Session | -5.9 ± 11.98 | -13.3 ± 15.25 | -0.2 ± 6.95 |
The PTGI is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales: relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. PTGI scores on a 6 point scale are: 0 - I did not experience this as a result of my crisis; 1 - I experienced this change to a very small degree as a result of my crisis; 2 - I experienced this change to a small degree as a result of my crisis; 3 - I experienced this change to a moderate degree as a result of my crisis; 4 - I experienced this change to a great degree as a result of my crisis; and 5 - I experienced this change to a very great degree as a result of my crisis. A total score is calculated by summing the responses to all 21 items, each rated on a 6-point scale, with higher scores indicating greater post-traumatic growth
| score on a scale | Active Dose 1 (125 mg) MDMA-assisted Therapy | Active Dose 2 (100 mg) MDMA-assisted Therapy | Comparator Dose (40 mg) MDMA-assisted Therapy |
|---|---|---|---|
| Change in Posttraumatic Growth Inventory (PTGI) From Baseline to One Month Post 2nd Experimental Session | 15.0 ± 19.71 | 16.2 ± 29.47 | 3.8 ± 24.65 |
Collected over All AEs from baseline to long-term follow-up (approximately 18 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Dose 1 MDMA (125 mg) and Psychotherapy (Stage 1) | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) |
| Active Dose 2 MDMA (100 mg) and Psychotherapy (Stage 1) | 0/9 (0%) | 1/9 (11.1%) | 6/9 (66.7%) |
| Comparator-dose MDMA (40 mg) and Psychotherapy (Stage 1) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Open-Label Session: Active Dose 1 | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Open-Label Session: Active Dose 2 | 0/9 (0%) | 1/9 (11.1%) | 3/9 (33.3%) |
| Crossover Open-Label Sessions: Comparator Dose | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| 12 Month Follow-up: Active Dose 1 | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| 12 Month Follow-up: Active Dose 2 | 0/9 (0%) | 1/9 (11.1%) | 1/9 (11.1%) |
| 12 Month Follow-up: Comparator Dose | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| SRRs: Active Dose 1 | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| SRRs: Active Dose 2 | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| SRRs: Comparator | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | Active Dose 1 MDMA (125 mg) and Psychotherapy (Stage 1) | Active Dose 2 MDMA (100 mg) and Psychotherapy (Stage 1) | Comparator-dose MDMA (40 mg) and Psychotherapy (Stage 1) | Open-Label Session: Active Dose 1 | Open-Label Session: Active Dose 2 | Crossover Open-Label Sessions: Comparator Dose | 12 Month Follow-up: Active Dose 1 | 12 Month Follow-up: Active Dose 2 | 12 Month Follow-up: Comparator Dose | SRRs: Active Dose 1 | SRRs: Active Dose 2 | SRRs: Comparator |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ruptured ovarian cystNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/13 | 0/9 | 0/6 | 0/12 | 0/9 | 0/5 | 0/11 | 1/9 | 0/5 | — | — | — |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/13 | 0/9 | 0/6 | 0/12 | 1/9 | 0/5 | 0/11 | 0/9 | 0/5 | — | — | — |
| Tibia fractureInjury, poisoning and procedural complications | 0/13 | 1/9 | 0/6 | 0/12 | 0/9 | 0/5 | 0/11 | 0/9 | 0/5 | — | — | — |
| Event | Active Dose 1 MDMA (125 mg) and Psychotherapy (Stage 1) | Active Dose 2 MDMA (100 mg) and Psychotherapy (Stage 1) | Comparator-dose MDMA (40 mg) and Psychotherapy (Stage 1) | Open-Label Session: Active Dose 1 | Open-Label Session: Active Dose 2 | Crossover Open-Label Sessions: Comparator Dose | 12 Month Follow-up: Active Dose 1 | 12 Month Follow-up: Active Dose 2 | 12 Month Follow-up: Comparator Dose | SRRs: Active Dose 1 | SRRs: Active Dose 2 | SRRs: Comparator |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnxietyPsychiatric disorders | 3/13 | 3/9 | 0/6 | 0/12 | 1/9 | 0/5 | 1/11 | 0/9 | 1/5 | 0/12 | 0/9 | 5/5 |
| InsomniaGeneral disorders | 0/13 | 0/9 | 0/6 | 0/12 | 0/9 | 0/5 | 0/11 | 0/9 | 0/5 | 0/12 | 0/9 | 3/5 |
| HeadacheGeneral disorders | 0/13 | 1/9 | 0/6 | 0/12 | 0/9 | 0/5 | 0/11 | 0/9 | 0/5 | 0/12 | 0/9 | 2/5 |
| Difficulty ConcentratingGeneral disorders | 0/13 | 0/9 | 0/6 | 0/12 | 0/9 | 0/5 | 0/11 | 0/9 | 0/5 | 0/12 | 0/9 | 2/5 |
| FatigueGeneral disorders | 0/13 | 0/9 | 0/6 | 0/12 | 0/9 | 0/5 | 0/11 | 0/9 | 0/5 | 0/12 | 0/9 | 2/5 |
| Jaw Clenching, Tight JawGeneral disorders | 0/13 | 0/9 | 0/6 | 0/12 | 0/9 | 0/5 | 0/11 | 0/9 | 0/5 | 0/12 | 0/9 | 2/5 |
| Low moodGeneral disorders | 0/13 | 0/9 | 0/6 | 0/12 | 0/9 | 0/5 | 0/11 | 0/9 | 0/5 | 0/12 | 0/9 | 2/5 |
| Need more sleepGeneral disorders | 0/13 | 0/9 | 0/6 | 0/12 | 0/9 | 0/5 | 0/11 | 0/9 | 0/5 | 0/12 | 0/9 | 2/5 |
| RuminationsGeneral disorders | 0/13 | 0/9 | 0/6 | 0/12 | 0/9 | 0/5 | 0/11 | 0/9 | 0/5 | 0/12 | 0/9 | 2/5 |
| VomitingGastrointestinal disorders | 3/13 | 0/9 | 0/6 | 0/12 | 0/9 | 0/5 | 0/11 | 0/9 | 0/5 | 0/13 | 0/9 | 0/6 |
Intent-to-Treat (ITT)
| Age, Continuous(years) | Active Dose 1 MDMA (125 mg) and Psychotherapy | Active Dose 2 MDMA (100 mg) and Psychotherapy | Comparator-dose MDMA (40 mg) and Psychotherapy | Total |
|---|---|---|---|---|
| Mean | 45.7 ± 15.53 | 39.6 ± 9.8 | 40 ± 11.71 | 42.4 ± 12.93 |
| Sex: Female, Male(Participants) | Active Dose 1 MDMA (125 mg) and Psychotherapy | Active Dose 2 MDMA (100 mg) and Psychotherapy | Comparator-dose MDMA (40 mg) and Psychotherapy | Total |
|---|---|---|---|---|
| Female | 8 | 6 | 5 | 19 |
| Male | 4 | 3 | 1 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Active Dose 1 MDMA (125 mg) and Psychotherapy | Active Dose 2 MDMA (100 mg) and Psychotherapy | Comparator-dose MDMA (40 mg) and Psychotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 12 | 8 | 6 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Active Dose 1 MDMA (125 mg) and Psychotherapy | Active Dose 2 MDMA (100 mg) and Psychotherapy | Comparator-dose MDMA (40 mg) and Psychotherapy | Total |
|---|---|---|---|---|
| White | 11 | 9 | 5 | 25 |
| American Indian Or Alaska Native | 0 | 0 | 1 | 1 |
| Other | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2013 to primary completion in Dec 2015, 30 months.
Results were first posted in Oct 2020, 4 years 10 months after primary completion. A results delay was requested in Mar 2018.
Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 30 months is above that.
Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine
Stress Disorders, Post-Traumatic →